Lincoln Pediatrics Clinic,pa
Lincoln Pediatrics Clinic,pa was paid $10.35M by Medicaid between Jan 2018 and Dec 2024, across 89 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 24% of everything it billed.
33Billing provider infoLINCOLN PEDIATRICS CLINIC,PA
LINCOLNTON, NC 28092
LINCOLNTON, NC 28092
33aNPI1477510659assigned 04/30/2006
33bProvider typeSpecialist
28Total paid$10.35M
24GClaims597,545
24DCodes billed89
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Specialist providers in North Carolina
Rank by total paid#6 of 172
Median peer was paid$83K
This provider vs. median125×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,007 | $1.14M | |
| 2019 | 45,747 | $1.20M | |
| 2020 | 44,777 | $1.01M | |
| 2021 | 95,132 | $1.97M | |
| 2022 | 128,210 | $2.31M | |
| 2023 | 142,003 | $1.76M | |
| 2024incomplete | 97,669 | $951K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24% | 50,777 | 35,245 | $2.46M |
| 99199 | Unlisted special service, procedure or report | 16% | 279,906 | 162,866 | $1.65M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 16% | 24,077 | 16,216 | $1.65M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 7.5% | 9,051 | 5,498 | $781K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 5.8% | 4,584 | 2,508 | $599K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.7% | 7,160 | 5,228 | $489K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.3% | 6,733 | 4,814 | $448K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.9% | 5,828 | 4,128 | $408K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.7% | 6,084 | 4,050 | $388K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2.5% | 18,007 | 12,194 | $258K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 2.2% | 9,652 | 6,671 | $224K |
| 99401 | 1.8% | 7,984 | 5,131 | $188K |
77 more codes
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.1% | 17,970 | $112K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,208 | $101K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,213 | $96K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 2,597 | $71K |
| D0145 | Oral evaluation for a patient under three years of age | <1% | 2,001 | $50K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,981 | $49K |
| 99058 | <1% | 2,744 | $36K | |
| 96127 | <1% | 10,391 | $33K | |
| 92551 | <1% | 16,850 | $23K | |
| D1206 | Topical application of fluoride varnish | <1% | 1,970 | $22K |
| 90651 | <1% | 2,675 | $21K | |
| 99381 | <1% | 276 | $21K | |
| 99421 | <1% | 972 | $20K | |
| 99050 | <1% | 952 | $19K | |
| 90734 | <1% | 2,237 | $15K | |
| 99070 | <1% | 2,608 | $13K | |
| 90474 | <1% | 891 | $12K | |
| 99441 | <1% | 531 | $12K | |
| 80061 | Lipid panel | <1% | 1,062 | $12K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 301 | $7K |
| 99173 | <1% | 14,934 | $7K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 79 | $6K |
| 0071A | <1% | 117 | $4K | |
| 99051 | <1% | 187 | $4K | |
| 81002 | <1% | 1,889 | $3K | |
| 82947 | <1% | 1,084 | $3K | |
| 69210 | <1% | 135 | $3K | |
| 83655 | <1% | 290 | $2K | |
| 90715 | <1% | 1,541 | $2K | |
| 90461 | <1% | 749 | $2K | |
| 96161 | <1% | 926 | $1K | |
| 0072A | <1% | 31 | $1K | |
| 87807 | <1% | 152 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 48 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 166 | $1K |
| 99177 | <1% | 2,464 | $903.06 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 13 | $792.22 |
| 99460 | <1% | 16 | $766.08 | |
| 99442 | <1% | 13 | $732.24 | |
| 81025 | <1% | 157 | $687.18 | |
| 85018 | <1% | 933 | $633.67 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 48 | $575.00 |
| 90619 | <1% | 263 | $526.47 | |
| 90686 | <1% | 960 | $518.88 | |
| 90473 | <1% | 47 | $421.47 | |
| 90633 | <1% | 2,591 | $375.28 | |
| 90621 | <1% | 202 | $370.01 | |
| 90716 | <1% | 973 | $244.00 | |
| 2001F | <1% | 9,127 | $243.45 | |
| 94760 | <1% | 1,757 | $230.34 | |
| 90656 | <1% | 2,527 | $132.64 | |
| 90707 | <1% | 885 | $79.73 | |
| 90698 | <1% | 3,589 | $61.00 | |
| 90696 | <1% | 928 | $58.02 | |
| 99188 | <1% | 28 | $45.30 | |
| 90713 | <1% | 113 | $32.15 | |
| 90680 | <1% | 2,271 | $15.00 | |
| 90670 | <1% | 4,195 | $4.00 | |
| 90710 | <1% | 953 | $3.00 | |
| 90744 | <1% | 2,093 | $1.00 | |
| 1160F | 0% | 9,186 | $0.00 | |
| 90655 | 0% | 325 | $0.00 | |
| 90700 | 0% | 516 | $0.00 | |
| 3078F | 0% | 3,873 | $0.00 | |
| 90658 | 0% | 188 | $0.00 | |
| 90649 | 0% | 15 | $0.00 | |
| G9920 | Screening performed and negative | 0% | 87 | $0.00 |
| 99072 | 0% | 99 | $0.00 | |
| 3008F | 0% | 4,242 | $0.00 | |
| 3074F | 0% | 4,057 | $0.00 | |
| 90647 | 0% | 456 | $0.00 | |
| 99000 | 0% | 176 | $0.00 | |
| 36416 | 0% | 275 | $0.00 | |
| 91307 | 0% | 160 | $0.00 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 35 | $0.00 |
| 90660 | 0% | 90 | $0.00 | |
| 90620 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOFRAD, MINA (TREASURER)